We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Vicotex

Download Mobile App




Dual Staining Kit Identifies High Grade Cervical Disease

By LabMedica International staff writers
Posted on 07 Jun 2010
A staining test is capable of identifying the underlying causes of high-grade cervical disease among women who are negative on the Papanicolau test (Pap smears). More...


The test uses advanced biomarkers to stain the cervical epithelium of women whose Pap smear results were equivocal but who were positive for Human papillomavirus (HPV). The smears are double stained with two immunoreactive markers revealing diagnostic proteins.

The codetection of the cell cycle regulatory protein p16 INK4a (p16) and a marker for cell proliferation Ki-67 in a single cell can be used as a screening test for high-grade cervical disease. Their presence in a single cell is an indicator of cell cycle deregulation that occurs during High Risk-HPV (HR-HPV) induced oncogenic transformation. The test is highly specific and highly sensitive for women most likely to have this condition. The test can be applied on conventional and liquid based cytology slides where brown cellular staining indicates p16 over-expression and red nuclear staining indicates Ki-67 expression.

In a prospective study of screening for cervical cancer in Germany, 427 women out of nearly 8,000 tested HPV positive when the Pap test was negative. These women were then managed with repeat testing and colposcopic examinations and biopsies as clinically indicated. Cervical smears from the same cases were tested with the dual staining method CINtecPLUS developed by mtm laboratories AG, (Heidelberg, Germany) and compared with the biopsy results. The test detected 91.9% of patients with cervical intraepithelial neoplasia (CIN), grade 2 (moderate dysplasia) and 96% of CIN grade 3 (severe dysplasia) cases.

The test is independent of age and HR-HPV infections. The results of the study were presented in May 2010 at the 5th European Congress of the European Federation for Colposcopy and Cervical Pathology in Berlin, Germany (EFC).

Robert J. Silverman, MA, the CEO of mtm laboratories stated, "the CINtec Plus kit is so accurate in detecting high grade disease in those women tested that they can immediately be followed up, while those who are negative can be triaged for routine testing."

Related Links:

mtm laboratories AG




Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
Gold Member
Aspiration System
VACUSAFE
CMV CLIA Diagnostic
CLIA CMV IgA Screen Group
New
Slide Scanner System
NanoZoomer S540MD
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image Credit: Shutterstock

Blood Test Could Guide Drug Selection to Prevent Repeat Heart Attacks and Strokes

Secondary prevention after myocardial infarction or stroke relies on antiplatelet therapy, yet responses vary widely and both recurrent thrombosis and bleeding remain persistent risks. In the United Kingdom,... Read more

Molecular Diagnostics

view channel
Image: Signatera uses ctDNA analysis to identify residual tumor-derived genetic material after definitive treatment (image credit: Adobe Stock)

Blood-Based MRD Test Predicts Recurrence Risk After Lung Cancer Surgery

Assessing recurrence risk after surgery for early-stage non-small cell lung cancer remains challenging, complicating adjuvant therapy and surveillance decisions. Blood-based molecular residual disease... Read more

Immunology

view channel
Image: Although many people harbor latent Epstein-Barr virus (EBV), growing evidence has linked the virus to MS pathobiology (Image Credit: Adobe Stock)

Blood EBV Activity Biomarkers May Predict Multiple Sclerosis Relapse Months Ahead

Predicting relapse in multiple sclerosis (MS) remains difficult, limiting opportunities for timely intervention and monitoring. Although many people harbor latent Epstein-Barr virus (EBV), growing evidence... Read more

Pathology

view channel
Image: A new study demonstrates that vascular features in colorectal tumors could serve as prognostic biomarkers of disease outcome. (Image Credit: iStock)

Tumor Blood Vessel Features May Help Predict Colorectal Cancer Survival

Colorectal cancer outcomes vary widely, and tumor biology remains a key determinant of prognosis. Because neoplasms depend on a vascular supply, differences in intratumoral vessels may influence survival.... Read more

Technology

view channel
Image: ADLM recommends that emerging AI tools follow the same professional oversight, quality, validation, and monitoring standards as traditional clinical testing within CLIA’s existing framework (Image Credit: Adobe Stock)

ADLM Calls for CLIA Updates to Support Safe AI Use in Laboratory Medicine

Clinical laboratories increasingly use artificial intelligence to verify, interpret, and report results, but safeguards under the Clinical Laboratory Improvement Amendments (CLIA) were designed in 1992.... Read more

Industry

view channel
Image: Central to the collaboration is the Enhanced Liver Fibrosis (ELF) test, a noninvasive blood test authorized in the U.S. to assess disease progression risk in patients with advanced fibrosis due to MASH and support patient management decisions. (Photo courtesy of Siemens Healthineers)

Siemens Healthineers and Novo Collaborate to Expand Access to Noninvasive Liver Testing

Metabolic dysfunction‑associated steatotic liver disease (MASLD) and its progressive form, metabolic dysfunction‑associated steatohepatitis (MASH), affect millions and are linked to obesity, type 2 diabetes,... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.